Enterprise Value
34.28M
Cash
8.099M
Avg Qtr Burn
-6.816M
Short % of Float
0.86%
Insider Ownership
28.20%
Institutional Own.
13.66%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Marzeptacog alfa (MarzAA) Details Hemophilia, Blood disorder, Rare genetic disease | Failed Discontinued | |
SQ Dalcinonacog alfa (DalcA) Details Hemophilia, Genetic disorder | Failed Discontinued |